stage for further investigation of cofactor and steroid receptor expression in various gynecologic disorders and raises many important issues for consideration of those future investigations.
Altered expression of endometrial regulatory proteins has been postulated as an underlying cause of infertility and recurrent pregnancy loss and as a contributing factor leading to neoplastic growth within the reproductive tract, including uterine fibrioids, endometriosis, and uterine cancers. Recent endometrial gene profiling studies illustrate the intricate downstream effects of ovarian steroids and the exquisite complexity of gene expression profiles over the course of the menstrual cycle. 18 . 19 These patterns of gene expression may be significandy altered in certain disease states. Comparison of the endometrium from women with and without endometriosis suggests a wide disparity in gene expression, consistent with an overall progesterone insensitivity.20 Suppression of endometriosis appears to correct such defects. 21 What forms the basis for this altered action of progesterone? Possibly this is a byproduct of an altered pattern of receptor or co activator expression in response to the inflammatory milieu of the disease.
Another striking example of enhanced endometrial responsiveness to estrogen and androgens is seen in polycystic ovarian syndrome (PCDS). These patients also exhibit significant variations in gene expression compared with normal fertile controls (Groll et al, Society for Gynecologic Investigation, abstract, 2003). In this common endocrine condition, miscarriage rates are high and cycle fecundity is 10w. 22 Elevated AR 23 and ERa and steroid receptor coactivators 24 have been specifically demonstrated in the endometrium of women with this disorder compared with normal fertile controls. Purposeful over-expression of coactivators, such as TIF2 and ALB 1 in vitro, demonstrate a marked increase in estrogen sensitivity, even in response to weak estrogens (Groll et aI, ASRM abstract, 2003). Correction of such defects is the subject of ongoing investigation.
The identification of all the receptors and cofactors in the endometrium alone will not be sufficient to elucidate their function. Collectively, we will have our hands full as we try to tease out the details of regulation and interaction between multiple receptors, coactivators, and repressors within complex tissues. Applying this infornlation to the clinical arena will require further investigation. Cancer risk and prevention are clearly at the top of the list as we consider where to take the next generation of studies of steroid receptor coactivators and repressors. Women with PCDS who exhibit elevated ERa and steroid receptor coactivators may be at heightened risk of endometrial hyperplasia or cancer. The rapidly growing leiomyomata might exhibit increased sensitivity to steroid hormones. Response of cancers to chemotherapy and selective estrogen modulators may depend on the complement of receptor isofonns and coactivators that are expressed within that cell. Heterogeneity of cofactors might allow selection for aberrant growth or resistance to hormonal therapy. Other gynecologic disorders will undoubtedly be found that are ultimately dependent on derangements in steroid receptors and cofactor expreSSIOn.
To investigate the interactions of coactivators and receptors in the reproductive tract, directed transfection of nuclear cofactors and gene knockout studies will be a valuable approach coming from the laboratory, whereas inspection and comparisons of defined subsets of infertile or abnormal endometrium will provide a valuable clinical approach. Medical management with pharmaceuticals that alter the estrogen, progesterone, or androgen milieu will also share the stage to address new therapeutic approaches that restore normal physiology to women with infertility or recurrent pregnancy loss. Development and applications of new selective estrogen, progesterone, and androgen modulators will also evolve faster with our growing understanding of how receptors and nuclear cofactors interact. Discovery of the molecular biology of this interaction will likely lead to new drugs and a new generation of hormonal antagonists. The impact of new powerful drugs will likely provide a way to selectively modulate the activity of steroid receptors within selected target tissues, such as breast, bone, and uterus. Combinations of hormones and selective estrogen modulators are already showing utility.
The study of steroid action in human target tissues is a moving target. The tale of how steroids work at the cellular level is a story that keeps getting better. Paraphrasing Kreb, the only thing keeping us from understanding nature is its sheer complexity. The study by Vienonen moves us closer to that goal.
